Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
CYTOXAN INJECTION |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent. |
| Generic Name |
|
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free. |
| Also |
|
• Cyclophosphamide
|
| Indications |
|
See literature. Malignant lymphomas, multiple myeloma, leukemias, advanced mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma and breast carcinoma. |
| Children |
|
See literature. |
| Adults |
|
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly. |
| Contraindications |
|
Severe bone marrow depression. |
| Precautions |
|
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity. |
| Adverse Reactions |
|
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions. |
| How Supplied |
Tabs—contact supplier
Single-use vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
